Global Tuberculosis Vaccine Market Trends, Business Overview, Industry Growth and Forecast to 2028

The global tuberculosis vaccine market is anticipated to grow at a significant CAGR of 8.4% during the forecast period 2022-2028. According to World Health Organization (WHO, an estimated 10 million individuals contracted tuberculosis (TB) in 2020 globally, with 5.6 million men, 3.3 million women, and 1.1 million children among them. The number of people receiving tuberculosis preventative therapy globally increased from 1 million in 2015 to 3.6 million in 2019.

Several researches are in pipeline which are significantly supporting the market growth. According to the WHO’s global tuberculosis (TB) report 2021, 25 medicines were in Phase I, Phase II, or Phase III studies in August 2021 for the treatment of drug-susceptible TB, MDR-TB, or TB infection.  6 repurposed drugs, 16 new chemical entities, 2 accelerated regulatory approval medications, and 1 drug recently approved by the US Food and Drug Administration for antibacterial and antifungal treatments on the limited population. Several combination regimens comprising novel or repurposed medicines, as well as host-directed treatment, are now being tested in Phase II or III studies. As of August 2021, 14 vaccine candidates were in clinical trials, including 2 in Phase I, 8 in Phase II, and 4 in Phase III. The only licensed vaccine for tuberculosis prophylaxis is the Bacille Calmette-Guerin (BCG) vaccine. The BCG vaccination, which was developed over a century ago and is now widely administered and protects children from developing severe forms of tuberculosis.

The global tuberculosis vaccine market is growing as a result of government and international efforts to minimize tuberculosis prevalence. For instance, India devised the National Strategic Plan (NSP) for TB Elimination 2017-2025 to combat the disease, which will address half a million of tuberculosis patients. Moreover, for the development of effective and affordable tuberculosis vaccines and medicines, India formed the India TB Research Consortium. In affluent countries like North America, a large percentage of tuberculosis cases are encountered, which is a driving factor for market growth in this region.

Some major players in the market include Pfizer Inc., Merck & Co. Inc., Dr Reddy’s Laboratories Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline PLC, Serum Institute of India Ltd., and Taj Pharmaceuticals Ltd. among others. The market players are helping significantly in the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay in the competition of the market. For instance, in July 2021, Biofabri and IAVI had partnered for efficacy trials of tuberculosis (TB) vaccine candidate MTBVAC. The candidate, designed by the Spanish researcher Dr Carlos Martin from the University of Zaragoza, was in-licensed and is being manufactured and developed by Biofabri, a subsidiary of the Zendal Group, in collaboration with the University of Zaragoza, IAVI, and Europe-based Tuberculosis Vaccine Initiative (TBVI).

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Pfizer Inc., Merck & Co. Inc., Dr Reddy’s Laboratories Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline PLC, Serum Institute of India Ltd., Taj Pharmaceuticals Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Tuberculosis Vaccine Market Report by Segment

By Type

• Immunotherapeutic Vaccine
• Booster Vaccine

By End-User

• Hospitals
• Clinics
• Others

Global Tuberculosis Vaccine Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa